KYMR Kymera Therapeutics, Inc. Insider Trading

CEO Mainolfi sells 50,000 KYMR shares at $119.00 via 10b5-1 plan; retains 666,568 shares plus options (104,284 equivalent shares)

Nello Mainolfi, Chief Executive Officer of Kymera Therapeutics, sold 50,000 shares (50.0K shares) for $5,950,000.00 ($6.0M) on 2026-07-07 as part of a pre-arranged 10b5-1 trading plan. This transaction reduced his direct holdings from 716,568 shares (716.6K shares) to 666,568 shares (666.6K shares), a reduction of 7.0% of pre-transaction holdings. The sale occurred at $119.00 while the current price stands at $119.24, placing the stock within 8.3% of its 52-week high of $130.05. Prior to this sell, the stock has risen 60.8% over 30 days and 36.8% over 90 days. As a scheduled transaction under a 10b5-1 plan, timing considerations are not applicable to this filing. Notably, the company remains unprofitable with net income of $-69,234,000.00 ($-69.2M) in the latest quarter, annual revenue growth of -16.7%, and a market cap of $9,808,394,793.12 ($9.8B). Mainolfi retains significant equity exposure through 666,568 direct shares and 104,284 shares in aggregate derivative holdings (stock options), preserving material ongoing ownership in the organization.

CFO Bruce N. Jacobs sells 77,109 shares for $8,864,828.98 at Kymera (KYMR); 10b5-1 plan execution.

Bruce N. Jacobs, CFO of Kymera Therapeutics, executed 8 separate sales totaling 77,109 shares for $8,864,828.98 on 2026-06-30, reducing his direct holdings from 321,992 shares to 244,883 shares (-23.9%). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The sales occurred at prices ranging from $110.54 to $117.70 per share (blended average $114.96), with the largest single transaction being 51,375 shares at $114.77. The company remains unprofitable (net income of -$69,234,000 on quarterly revenue of $34,365,000), and fundamental trends show annual revenue decline of -16.7% year-over-year. Notably, the CFO's prior five sales at KYMR (all on 2026-03-04 and 2026-03-02) were followed by consistently negative returns at both the 30-day and 90-day horizons, with 90-day outcomes ranging from -7.2% to -17.7%. The current stock price of $113.51 represents a -12.7% retreat from the 52-week high of $130.05, though the stock has rallied +59.2% over the prior 30 days.

KYMR CEO Nello Mainolfi sells 80,000 shares for $9,223,527.48 via 5 separate transactions; 10b5-1 plan

Nello Mainolfi executed 5 separate sales totaling 80,000 shares (80.0K shares) for $9,223,527.48 ($9.2M) on 2026-07-01 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 746,568 shares to 666,568 shares (-10.7% vs pre-transaction). The insider retains 135,559 shares in stock options. Kymera is trading 12.7% below its 52-week high of $130.05 despite a 30-day rally of +59.2%, though the company posted a net loss of $69,234,000.00 over its most recent full fiscal year against revenue of $34,365,000.00, with annual revenue declining 16.7% year-over-year. His prior open-market sales across all tickers show a cross-ticker 90-day average return of +4.8%, while his prior Kymera sales on 2026-02-25 returned -10.0% and -10.6% over 90 days respectively. Because this transaction is scheduled under a 10b5-1 plan, it reflects a pre-set commitment rather than a discretionary timing decision.

Director Booth executes 14 separate sales totaling 76,650 shares for $8,281,904.62 under 10b5-1 plan at KYMR on 2026-06-29.

Bruce Booth, a director of Kymera Therapeutics, executed 14 separate sales totaling 76,650 shares for $8,281,904.62 on 2026-06-29, as part of a pre-arranged 10b5-1 trading plan—a scheduled, non-discretionary reduction of his stake from 539,506 to 462,856 shares. The transaction occurs at prices ranging from $105.78 to $111.20 per share, with a blended average of $108.05, against a current stock price of $113.51 and a 52-week high of $130.05. Kymera remains unprofitable (most recent full-year net income was negative), with revenue declining -16.7% year-over-year, making the magnitude of this director's divestiture—reducing holdings by 14.2%—a structural reallocation rather than a signal derived from near-term conviction. The 10b5-1 framework and recent repeated sales at KYMR (five prior sales on 2026-06-25) indicate an established, programmatic approach to liquidity management.

Director Bruce Booth sold 31,283 shares for $3.4M (blended avg $109.48) on 2026-06-29 via 10b5-1 plan; now holds 461,794 shares at KYMR.

Bruce Booth, a Director at Kymera Therapeutics, executed 8 separate sales totaling 31,283 shares for $3,424,800.35 on 2026-06-29 as part of a pre-arranged 10b5-1 trading plan. The company is unprofitable with net income of $-69,234,000.00 and annual revenue growth of -16.7%, which provides material context for the timing of this disposal. This sale follows four prior scheduled dispositions at the same ticker on 2026-06-25, indicating a planned program of steady liquidation rather than a discretionary response to market conditions. The current stock price of $114.67 is -11.8% from the 52-week high of $130.05, yet the stock has appreciated 40.8% over the past 30 days and 35.0% over 90 days, suggesting recent momentum that may reflect sector-wide or company-specific developments unrelated to this director's pre-planned equity reduction schedule.

Director Bruce Booth sold 513,245 shares ($56.5M) over 30 transactions in two days on 10b5-1 plan scheduled sales at KYMR.

Bruce Booth, a Director at unprofitable Kymera Therapeutics, sold 513.2K shares for $56,460,136.28 across 30 separate transactions on June 26–29, 2026, reducing his holdings by 52.4% from 979.3K to 466.1K shares. The sale is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary; this removes any inference about insider motivation or conviction based on timing. The company reported $34.4M in latest-quarter revenue, full-year net income of negative $69.2M, and annual revenue decline of 16.7%, indicating ongoing operational losses. The transaction's scale—$56.5M and more than half the insider's pre-transaction stake—is material, but the 10b5-1 framework precludes characterization of the sale timing as strategic judgment. The multi-day, multi-price execution pattern reflects the mechanics of a pre-programmed disposition plan rather than discrete decision-making.

Partners L P/Il Bvf sold 1,630,658 shares for $173,665,077.00 at $106.50, reducing KYMR stake 95.4%

Partners L P/Il Bvf executed 4 separate sales totaling 1,630,658 shares for $173,665,077.00 at $106.50 on 2026-06-26, reducing his holding from 1,709,445 shares to 78,787 shares—a -95.4% net reduction in position size. The stock has since rallied to $116.46 (current price), up 44.2% over the prior 30 days and up 49.0% over 90 days, indicating the sales preceded a sharp uptrend. Against his cross-ticker track record, his prior 15 sells averaged a 90-day return of +1.3% with a well-timed rate of 58.33%; this near-complete divestiture at $106.50 before the subsequent gains represents a marked departure from his historical sell patterns. The company remains unprofitable (net income $-69,234,000.00 for the latest full year) with declining revenue (-16.7% annual growth), providing fundamental context for the substantial liquidation.

Director Bruce Booth sells 285.7K shares (35.0% reduction) for $34.8M at KYMR via scheduled 10b5-1 plan

Bruce Booth executed 22 separate sales totaling 285,684 shares for $34,812,908.93 on a single day, reducing his holdings from 815,402 to 529,718 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The company context is material: KYMR reported revenue of $34,365,000.00 with net income of $-69,234,000.00 in its latest quarter, and annual revenue growth of -16.7%, indicating the company is unprofitable and shrinking. The stock is currently at $116.46, down 10.4% from its 52-week high of $130.05, though up 44.2% over 30 days and 49.0% over 90 days. Booth's prior sales at KYMR show negative 30-day and 90-day returns (ranging from -5.8% to -18.0% across five earlier trades at this ticker), and his cross-ticker track record across 20 prior sells averaged -10.6% over 30 days and -4.5% over 90 days.

Director Bruce Booth sold 398,765 shares (41.4% of holdings) for $43,987,354.76 via 10b5-1 plan across three days.

Bruce Booth, a director at Kymera Therapeutics, executed 30 separate sales totaling 398.8K shares for $44.0M across June 23–25, 2026, reducing his stake by 41.4% to 564,668 shares post-transaction. This is a pre-arranged 10b5-1 trading plan—scheduled, not discretionary—so it does not reflect real-time market judgment. Kymra's fundamentals are challenging: the company reported revenue of $34,365,000.00 in the latest quarter with net income of $-69,234,000.00, and annual revenue growth of -16.7%; the stock is also down 10.4% from its 52-week high of $130.05 despite a 44.2% gain over the past 30 days. Booth's same-ticker history shows mixed outcomes: his prior four sales at KYMR (excluding duplicates) posted 30-day returns ranging from -5.8% to -18.0% and 90-day returns from -9.7% to -18.0%, suggesting his prior sales at this security have not captured strong subsequent upside.

Director Bruce Booth sells 31,798 shares (31.8K) at $103.75 blended average under 10b5-1 plan; stock down 5.3% from 52-week high but up 26.1% in 30 days.

Bruce Booth sold 31,798 shares across 4 separate transactions on 2026-06-22 at prices of $103.42 and $104.38, realizing $3,299,037.16, pursuant to a pre-arranged 10b5-1 trading plan. As a scheduled sale, this transaction carries no timing signal. Booth retains 613,762 shares post-transaction, representing a 4.9% reduction from his pre-transaction holdings. The company reported $34.4M quarterly revenue with $-69.2M net income, negative annual growth of -16.7%, and remains unprofitable, yet the stock has appreciated 26.1% over the past 30 days and 33.6% over 90 days. Booth's prior sales at KYMR show mixed historical returns: three sales posted negative 30- and 90-day returns (ranging from -5.8% to -18.0%), while his cross-ticker track record across 20 prior sales averaged -10.6% over 30 days and -4.5% over 90 days. The substantial rally following recent execution warrants attention to whether valuation has decoupled from fundamentals.